A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

NCT06839066 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG: HLX43 DOSE 1
DRUG: HLX43 DOSE 2
DRUG: HLX43 DOSE 3

Sponsor

Shanghai Henlius Biotech